These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9577640)

  • 1. [Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
    Tabata M; Yoshida M; Izumi T; Kawano C; Kuribara R; Toshima M; Omine K; Takatoku M; Uchida M; Kirito K; Miyazato A; Takahashi H; Hoshino M; Terui Y; Tomizuka H; Otsuki T; Shimizu R; Tsunoda J; Muroi K; Furukawa Y; Amemiya Y; Imagawa S; Komatsu N; Suzuki T; Miura Y
    Rinsho Ketsueki; 1998 Mar; 39(3):176-84. PubMed ID: 9577640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
    [No Abstract]   [Full Text] [Related]  

  • 5. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q; Liu L; Zhang Y; Li X; Wu D
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress of chemotherapy in adult acute leukemia].
    Ohno R
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):431-6. PubMed ID: 7887634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
    Paśnicki M
    Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of acute myelogenous leukemia in patients more than 80 years old].
    Takeyama H; Yamamoto Y; Miyata Y; Yamada H; Watanabe E; Aoki H; Iinuma M
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1089-93. PubMed ID: 9239161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
    Wei G; Ni W; Chiao JW; Cai Z; Huang H; Liu D
    J Hematol Oncol; 2011 Nov; 4():46. PubMed ID: 22082134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of aggressive chemotherapy for myelodysplastic syndromes.
    Dohy H; Kyo T
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
    Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
    Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
    Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
    Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.